Sai Life Sciences Jumps 8% As Q3 Profit Soars 86%

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Sai Life Sciences Jumps 8% As Q3 Profit Soars 86%
Overview

Sai Life Sciences shares surged 8% Friday after reporting an 86.3% year-on-year profit jump to ₹100 crore for Q3 FY26. Revenue climbed 26.5% to ₹556 crore, with EBITDA rising 56.8% and margins expanding. The company attributed growth to enhanced technology platforms and digital adoption, projecting sustained momentum.

Stellar Q3 Performance Fuels Share Rally

Sai Life Sciences Ltd. shares surged by over 8% on Friday, marking the steepest intraday gain since August 8 last year. This significant jump followed the company's announcement of a remarkable 86.3% year-on-year increase in net profit for the December quarter of fiscal year 2026 (Q3 FY26). The stock reached an intraday high of ₹877 before paring gains to trade approximately 4.9% higher, outperforming the broader market which saw the Nifty 50 decline by 0.35%.

Deep Dive into Financials

The company's consolidated net profit for the quarter reached ₹100 crore, a substantial rise from ₹53.9 crore in the same period last year. Revenue also demonstrated robust growth, climbing 26.5% to ₹556 crore from ₹440 crore year-on-year. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) saw an impressive 56.8% increase, reaching ₹188 crore from ₹120 crore previously. Crucially, the EBITDA margin expanded significantly to 33.8%, up from 27.2% in the corresponding quarter of the prior year, indicating improved operational efficiency.

Management Confidence and Strategic Investments

Krishna Kanumuri, Managing Director and CEO, attributed the strong performance to the company's strengthened technology platforms, driven by greater adoption of digital, AI-enabled, and modern chemistry approaches. "We are well positioned to support the next phase of innovation while creating long-term value for all stakeholders," Kanumuri stated, expressing confidence in sustaining growth momentum. Chief Financial Officer Siva Chittor highlighted ongoing investments in infrastructure, with ₹405 crore invested in capital expenditure so far against a planned outlay of ₹700 crore for FY26. This investment reinforces the company's commitment to building scalable, future-ready facilities.

Outlook and Investor Call

With strengthened capabilities, a solid order pipeline, and a resilient operating foundation, Sai Life Sciences anticipates another year of strong and profitable growth. The company is scheduled to conduct an earnings call on February 6, 2026, at 4:00 PM IST to further discuss its financial and business performance.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.